Nivolumab plus standard of care vs standard of care for first-line metastatic colorectal cancer

Phase 2, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Nivolumab plus standard of care with Standard of care (2 arms). Primary endpoint: Progression-free survival by blinded independent central review. Started Feb 2018; status: terminated.